Development of thrombolytic therapy for stroke: a perspective

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2002-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.11.11.1623PMID 12437508
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Major ongoing stroke trials.

  2003cited by this paper
• Effects of the Spin Trap Agent Disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) on Intracerebral Hemorrhage in a Rabbit Large Clot Embolic Stroke Model: Combination Studies With Tissue Plasminogen Activator

  2002cited by this paper
• Microplasmin: A Novel Thrombolytic That Improves Behavioral Outcome After Embolic Strokes in Rabbits

  2002influential reference
• ATLANTIS Trial: Results for Patients Treated Within 3 Hours of Stroke Onset

  2002cited by this paper
• Thrombolytic Therapy Within 3 to 6 Hours After Onset of Ischemic Stroke: Useful or Harmful?

  2002cited by this paper
• Neuroprotective Effects of the Spin Trap Agent Disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-Oxide (Generic NXY-059) in a Rabbit Small Clot Embolic Stroke Model: Combination Studies With the Thrombolytic Tissue Plasminogen Activator

  2002cited by this paper
• Thrombolysis for acute ischaemic stroke: consumer involvement in design of new randomised controlled trial

  2002cited by this paper
• Thrombolysis for acute ischemic stroke: still a treatment for the few by the few.

  2002cited by this paper
• Comparison of Pharmacokinetics of Lanoteplase and Alteplase During Acute Myocardial Infarction

  2002cited by this paper
• Monteplase reduces infarct volume and hemorrhagic transformation in rat model of embolic stroke

  2002cited by this paper
• Hemorrhagic transformation following ischemic stroke: Significance, causes, and relationship to therapy and treatment

  2002influential reference
• The Nonpeptide Glycoprotein IIb/IIIa Platelet Receptor Antagonist SM-20302 Reduces Tissue Plasminogen Activator–Induced Intracerebral Hemorrhage After Thromboembolic Stroke

  2002cited by this paper
• Optimal Timing of Thrombolytic Therapy in Acute Ischaemic Stroke

  2002cited by this paper
• Improving Delivery of Acute Stroke Therapy: The TLL Temple Foundation Stroke Project

  2002cited by this paper
• Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.

  2002cited by this paper
• Treatment of acute ischemic stroke.

  2001cited by this paper
• Vampire Bat Plasminogen Activator DSPA-Alpha-1 (Desmoteplase): A Thrombolytic Drug Optimized by Natural Selection

  2001cited by this paper
• Comparison of TNK With Wild-Type Tissue Plasminogen Activator in a Rabbit Embolic Stroke Model

  2001cited by this paper
• Thrombolytic therapy for ischemic stroke—A review. Part I—Intravenous thrombolysis

  2001cited by this paper
• Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke

  2001cited by this paper
• Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II)

  2001cited by this paper
• Pharmacological Effects of the Spin Trap Agents N-t-Butyl-Phenylnitrone (PBN) and 2,2,6,6-Tetramethylpiperidine-N-Oxyl (TEMPO) in a Rabbit Thromboembolic Stroke Model: Combination Studies With the Thrombolytic Tissue Plasminogen Activator

  2001cited by this paper
• Thrombolytic therapy for ischemic stroke—A review. Part II—Intra-arterial thrombolysis, vertebrobasilar stroke, phase IV trials, and stroke imaging

  2001cited by this paper
• Reducing Bleeding Complications After Thrombolytic Therapy for Stroke

  2001influential reference
• Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial.

  2001cited by this paper
• Plasmin Induces Local Thrombolysis without Causing Hemorrhage: A Comparison with Tissue Plasminogen Activator in the Rabbit

  2001cited by this paper
• Immunohistochemistry of matrix metalloproteinases in reperfusion injury to rat brain: activation of MMP-9 linked to stromelysin-1 and microglia in cell cultures.

  2001cited by this paper
• Revival of Plasmin as a Therapeutic Agent?

  2001cited by this paper
• Pharmacokinetic properties of a novel tissue-type plasminogen activator pamiteplase after single intravenous administration to rats, dogs, and monkeys.

  2001cited by this paper
• Depletion of circulating alpha(2)-antiplasmin by intravenous plasmin or immunoneutralization reduces focal cerebral ischemic injury in the absence of arterial recanalization.

  2001influential reference
• Tenecteplase: a review.

  2001cited by this paper
• The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.

  2000cited by this paper
• Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study.

  2000influential reference
• Molecular mechanisms of plasminogen activation: bacterial cofactors provide clues.

  2000cited by this paper
• The impact of stroke.

  2000cited by this paper
• Early stroke treatment associated with better outcome: the ninds rt-pa stroke study

  2000cited by this paper
• Intra-arterial Prourokinase for Acute Ischemic Stroke

  2000cited by this paper
• Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II.

  2000cited by this paper
• Postischemic intracarotid treatment with TNK-tPA reduces infarct volume and improves neurological deficits in embolic stroke in the unanesthetized rat.

  2000cited by this paper
• Thrombolysis in acute ischemic stroke: controlled trials and clinical experience.

  1999cited by this paper
• Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

  1999influential reference
• New plasminogen activators: A clinical review

  1999cited by this paper
• Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice.

  1999cited by this paper
• Newer thrombolytic agents.

  1999cited by this paper
• Evaluation of early computed tomographic findings in acute ischemic stroke.

  1999cited by this paper
• Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial

  1999cited by this paper
• The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study.

  1998cited by this paper
• Local intra-arterial thrombolysis in acute ischemic stroke.

  1998cited by this paper
• Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

  1998cited by this paper
• The ECASS 3-Hour Cohort

  1998cited by this paper
• TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators.

  1998cited by this paper
• tPA-associated reperfusion after acute stroke demonstrated by SPECT.

  1998influential reference
• Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I.

  1998cited by this paper
• TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.

  1997cited by this paper
• Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke.

  1997cited by this paper
• Hyperacute stroke therapy with tissue plasminogen activator.

  1997cited by this paper
• Tissue plasminogen activator for acute ischemic stroke.

  1996influential reference
• Thrombolytic therapy with streptokinase in acute ischemic stroke.

  1996cited by this paper
• Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.

  1996influential reference
• Molecular biology of plasminogen activators: what are the clinical implications of drug design?

  1996cited by this paper
• Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group.

  1995cited by this paper
• Risk-Benefit Of Thrombol Ysis

  1995cited by this paper
• Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

  1995cited by this paper
• Tissue plasminogen activator for acute ischemic stroke.

  1995cited by this paper
• Risk-benefit of thrombolysis.

  1995cited by this paper
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.

  1995cited by this paper
• Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke

  1995influential reference
• Plasminogen mutants activated by thrombin. Potential thrombus-selective thrombolytic agents.

  1994cited by this paper
• A faster-acting and more potent form of tissue plasminogen activator.

  1994cited by this paper
• Dose-related efficacy and bleeding complications of double-chain tissue plasminogen activator in acute myocardial infarction. The Wellcome Tissue Plasminogen Activator Study Group.

  1993cited by this paper
• Tissue Plasminogen Activator: Reduction of Neurologic Damage After Experimental Embolic Stroke

  1988cited by this paper
• Tissue plasminogen activator.

  1988cited by this paper
• Tissue plasminogen activator reduces neurological damage after cerebral embolism.

  1985cited by this paper

• Stroke: Evolution of newer treatment modalities for acute ischemic stroke

  2024cites this paper
• A comprehensive review of stroke-related signaling pathways and treatment in western medicine and traditional Chinese medicine

  2023cites this paper
• Effect of thrombolysis in a mobile stroke unit versus in hospital for patients with ischemic stroke

  2021cites this paper
• Drug Repurposing: Promises of Edaravone Target Drug in Traumatic Brain Injury.

  2020cites this paper
• CNB‐001, a pleiotropic drug is efficacious in embolized agyrencephalic New Zealand white rabbits and ischemic gyrencephalic cynomolgus monkeys

  2019influential citation
• Intravenous xenogeneic human cardiosphere‐derived cell extracellular vesicles (exosomes) improves behavioral function in small‐clot embolized rabbits

  2018cites this paper
• Cytoprotective Drug-Tissue Plasminogen Activator Protease Interaction Assays: Screening of Two Novel Cytoprotective Chromones

  2017cites this paper
• Reflections on Neuroprotection Research and the Path Toward Clinical Success

  2017cites this paper
• Chapter 38 Difficult Path to Treating Acute Ischemic Stroke Patients with Transcranial Near-Infrared Laser Therapy

  2016cites this paper
• A novel method to promote behavioral improvement and enhance mitochondrial function following an embolic stroke.

  2016cites this paper
• A sensory stimulation-based collateral therapeutic for ischemic stroke: new insights and limitations

  2015cites this paper
• A blinded, randomized study of L-arginine in small clot embolized rabbits.

  2015cites this paper
• The March of Thrombolytic Therapy for Acute Ischemic Stroke to Clinical Trials: Pre-clinical Thrombolysis and Adjuncts to Thrombolysis Research

  2015influential citation
• Critical Early Thrombolytic and Endovascular Reperfusion Therapy for Acute Ischemic Stroke Victims: a Call for Adjunct Neuroprotection

  2015cites this paper
• A Cost-Effective Rabbit Embolic Stroke Bioassay: Insight into the Development of Acute Ischemic Stroke Therapy

  2015cites this paper
• Protective Effect of Some Medicinal Plant Phytoconstituents against Transient Middle Cerebral Artery Occlusion Induced Focal Cerebral Ischaemia and Consequent Cerebral Infarction in Mice

  2015cites this paper
• Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke

  2014cites this paper
• rLOAD: does sex mediate the effect of acute antiplatelet loading on stroke outcome

  2014cites this paper
• Antiplatelet Loading Improves Behavioral Outcome in a Rabbit Model of Stroke

  2013cites this paper
• A Clinically Relevant Rabbit Embolic Stroke Model for Acute Ischemic Stroke Therapy Development: Mechanisms and Targets

  2012cites this paper
• A series of novel neuroprotective blood brain barrier penetrating flavonoid drugs to treat acute ischemic stroke.

  2012cites this paper
• CeeTox Analysis to De-risk Drug Development: The Three Antioxidants (NXY-059, Radicut, and STAZN)

  2012cites this paper
• Use of thrombolytic therapy beyond current recommendations for acute ischaemic stroke

  2012cites this paper
• Emerging Therapies: Pleiotropic Multi-target Drugs to Treat Stroke Victims

  2011cites this paper
• A novel human microplasmin fold: new perspective to thrombosis treatment

  2011cites this paper
• Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective

  2011cites this paper
• Neuroprotective effects of andrographolide in a rat model of permanent cerebral ischaemia

  2010influential citation
• Taking a light approach to treating acute ischemic stroke patients: Transcranial near-infrared laser therapy translational science

  2010cites this paper
• Intra-arterial versus intra-venous thrombolysis within and after the first 3 hours of stroke onset

  2010influential citation
• Translational Stroke Research Using a Rabbit Embolic Stroke Model: A Correlative Analysis Hypothesis for Novel Therapy Development

  2010cites this paper
• Simvastatin improves clinical scores in a rabbit multiple infarct ischemic stroke model: synergism with a ROCK inhibitor but not the thrombolytic tissue plasminogen activator.

  2010cites this paper
• Efficacy and safety profile of the carotenoid trans sodium crocetinate administered to rabbits following multiple infarct ischemic strokes: a combination therapy study with tissue plasminogen activator.

  2010cites this paper
• A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy?

  2010cites this paper
• Different therapy options protecting microvasculature after experimental cerebral ischaemia and reperfusion

  2010cites this paper
• Modulation of Multiple Pathways Involved in the Maintenance of Neuronal Function by Fisetin

  2009cites this paper
• The lipophilic multifunctional antioxidant edaravone (radicut) improves behavior following embolic strokes in rabbits: a combination therapy study with tissue plasminogen activator.

  2009cites this paper
• Effect of internal carotid artery reperfusion in combination with Tenecteplase on clinical scores and hemorrhage in a rabbit embolic stroke model.

  2009cites this paper
• Toward Safer Thrombolytic Agents in Stroke: Molecular Requirements for NMDA Receptor-Mediated Neurotoxicity

  2008cites this paper
• Carbamylated erythropoietin to treat neuronal injury: new development strategies

  2008cites this paper
• Recent advances in intra-arterial thrombolysis

  2008cites this paper
• The many faces of erythropoietin: from erythropoiesis to a rational neuroprotective strategy – correspondence

  2008cites this paper
• Enzymatic vitreolysis with recombinant microplasminogen and tissue plasminogen activator

  2008cites this paper
• The many faces of erythropoietin: from erythropoiesis to a rational neuroprotective strategy

  2008cites this paper
• The many faces of erythropoietin: from erythropoiesis to a rational neuroprotective strategy--correspondence.

  2008cites this paper
• A novel approach to screening for new neuroprotective compounds for the treatment of stroke.

  2007cites this paper
• Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: an extended therapeutic window study using continuous and pulse frequency delivery modes.

  2007cites this paper
• Advances in hemorrhagic stroke therapy: conventional and novel approaches

  2007cites this paper
• Neuroprotection and stroke: time for a compromise

  2007cites this paper
• Microplasmin and tissue plasminogen activator: comparison of therapeutic effects in rat stroke model at multiparametric MR imaging.

  2007cites this paper
• Microplasmin and Tissue Plasminogen Activator: ComparisonofTherapeuticEffectsin RatStrokeModelatMultiparametric

  2007cites this paper
• Advances in ischemic stroke treatment: neuroprotective and combination therapies

  2007influential citation
• The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: synergism with tissue plasminogen activator.

  2007cites this paper
• Development of the nitrone-based spin trap agent NXY-059 to treat acute ischemic stroke.

  2006cites this paper
• Monitoring of Glycoprotein Products in Cell Culture Lysates Using Lectin Affinity Chromatography and Capillary HPLC Coupled to Electrospray Linear Ion Trap‐Fourier Transform Mass Spectrometry (LTQ/FTMS)

  2006cites this paper
• 3α-OL-5-β-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: Synergism with tissue plasminogen activator

  2006cites this paper
• 3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator.

  2006cites this paper
• Tissue plasminogen activator combined with human recombinant deoxyribonuclease is effective therapy for empyema in a rabbit model.

  2006cites this paper
• Safety of in vivo pharmacologic vitreolysis with recombinant microplasmin in rabbit eyes.

  2005cites this paper
• Preclinical Testing of Thrombolytic Therapy for Acute Ischemic Stroke

  2005cites this paper
• Acute stroke: evaluation and treatment.

  2005cites this paper
• Voltage-gated cation channel modulators for the treatment of stroke

  2005cites this paper
• Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores.

  2004cites this paper
• Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits.

  2004cites this paper
• Pharmacology of caffeinol in embolized rabbits: clinical rating scores and intracerebral hemorrhage incidence.

  2004cites this paper
• The complexity of tissue-type plasminogen activator: can serine protease inhibitors help in stroke management?

  2004cites this paper
• Zivin Rabbits : Synergism With Low-Dose Tissue Plasminogen Activator Ebselen , a Seleno-Organic Antioxidant , Is Neuroprotective After Embolic Strokes in

  2003cites this paper
• Ebselen, a Seleno-Organic Antioxidant, Is Neuroprotective After Embolic Strokes in Rabbits: Synergism With Low-Dose Tissue Plasminogen Activator

  2003cites this paper
• Thrombolysis in the treatment of acute ischemic stroke

  2003cites this paper